Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
acquired_by_Purdue_Pharma_L.P.
|
| gptkbp:advertising |
responsible for marketing strategies
direct-to-consumer advertising |
| gptkbp:campaigns |
'Pain is the 5th Vital Sign' campaign
|
| gptkbp:CEO |
gptkb:Craig_Landau
resigned amid legal challenges |
| gptkbp:claims |
multiple lawsuits regarding opioid crisis
|
| gptkbp:community |
struggled with public relations crisis
|
| gptkbp:community_impact |
significant impact on public health
impacted_communities_across_the_U.S. |
| gptkbp:community_outreach |
engaged in community outreach programs
|
| gptkbp:controversy |
aggressive marketing of opioids
|
| gptkbp:court |
involved in ongoing opioid litigation
|
| gptkbp:criticism |
accused of misleading marketing practices
|
| gptkbp:culturalHeritage |
limited liability company
|
| gptkbp:dosageForm |
increased_opioid_prescriptions_in_the_U.S.
|
| gptkbp:drugInterdiction |
contributed to rising rates of opioid addiction
developed response strategies for opioid crisis developing non-opioid pain relief alternatives linked_to_the_opioid_epidemic_in_the_U.S. |
| gptkbp:educational_programs |
provided opioid education resources.
|
| gptkbp:employees |
approximately 1,000
|
| gptkbp:exportMarkets |
not publicly traded
|
| gptkbp:financialPerformance |
declining revenue post-2018
|
| gptkbp:founded |
1996
|
| gptkbp:founder |
gptkb:John_Purdue_Gray
|
| gptkbp:future_plans |
proposed plan to address opioid crisis
|
| gptkbp:governance |
underwent changes in corporate governance practices
|
| gptkbp:headquarters |
gptkb:Stamford,_Connecticut
|
| https://www.w3.org/2000/01/rdf-schema#label |
Purdue Pharma
|
| gptkbp:investmentFocus |
invested in addiction recovery initiatives
|
| gptkbp:legal_principle |
facing numerous lawsuits
|
| gptkbp:legal_representation |
reached multiple legal settlements
settled lawsuits for billions |
| gptkbp:legalStatus |
spent millions on legal defense
|
| gptkbp:marketingStrategy |
aggressive opioid marketing tactics
|
| gptkbp:notableEvent |
gptkb:OxyContin
|
| gptkbp:notableFeature |
$8.3 billion settlement in 2020
|
| gptkbp:outcome |
found liable for deceptive practices
|
| gptkbp:parent_company |
gptkb:Purdue_Pharma_L.P.
|
| gptkbp:partnerships |
collaborated with various healthcare organizations
|
| gptkbp:philanthropy |
donations to addiction treatment programs
|
| gptkbp:productLine |
pain relief medications
|
| gptkbp:products |
developed extended-release formulations
|
| gptkbp:public_perception |
held public hearings on opioid crisis
widely criticized for opioid epidemic contribution |
| gptkbp:reach |
operates_primarily_in_the_U.S.
|
| gptkbp:recalls |
OxyContin_reformulation
|
| gptkbp:reform |
reformulated_OxyContin_to_deter_abuse
|
| gptkbp:regulatoryCompliance |
facing compliance issues with regulations
increased_scrutiny_from_FDA_and_DEA |
| gptkbp:research |
funded addiction research initiatives
|
| gptkbp:research_focus |
pain management
|
| gptkbp:revenue |
$3 billion (2018)
|
| gptkbp:scholarships |
September 2019
|
| gptkbp:subsidiary |
gptkb:Purdue_Pharma_L.P.
|